AI assistant
DEXCOM INC — Director's Dealing 2022
Mar 5, 2022
30198_dirs_2022-03-04_504d6cd9-0bd4-44c0-8fd6-2ec9e03d1840.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-03-04
Reporting Person: Sylvain Jereme M (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-04 | Common Stock | S | 600 | $422.94 | Disposed | 14662 | Direct |
Footnotes
F1: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 12,684 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022.